Allegra ODT and Eluxadoline
Determining the interaction of Allegra ODT and Eluxadoline and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Eluxadoline may increase the blood levels and effects of fexofenadine. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with eluxadoline may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eluxadoline. The interaction has been demonstrated for rosuvastatin, a known substrate of both OATP 1B1 and BCRP. When a single 20 mg dose of rosuvastatin was given during multiple dosing of eluxadoline 100 mg twice daily, rosuvastatin peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 18% and 40%, respectively, compared to administration of rosuvastatin alone. Similar results were reported for the active major metabolite, n-desmethyl rosuvastatin.
MANAGEMENT: Caution is advised when eluxadoline is used concomitantly with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eluxadoline is added to or withdrawn from therapy.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Viberzi (eluxadoline)." Actavis Pharma, Inc., Parsippany, NJ.
Generic Name: fexofenadine
Brand name: Allegra ODT, Allegra, Aller-Ease, Children's Allegra Allergy, Mucinex Allergy, Wal-Fex, Allegra 24 Hour Allergy, Allegra Allergy, Children's Allegra ODT, Allergy Relief, Allegra OTC
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Allegra ODT-Elvitegravir
- Allegra ODT-Elvitegravir, cobicistat, emtricitabine, and tenofovir
- Allegra ODT-Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide
- Allegra ODT-Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate
- Allegra ODT-Elzonris
- Allegra ODT-Emapalumab
- Eluxadoline-Allegra-D
- Eluxadoline-Allegra-D 12 hour
- Eluxadoline-Allegra-D 24 Hour
- Eluxadoline-Aller-Chlor
- Eluxadoline-Aller-Ease
- Eluxadoline-AllerDur